Aveanna Healthcare (NASDAQ:AVAH) Stock Price Expected to Rise, BMO Capital Markets Analyst Says

Aveanna Healthcare (NASDAQ:AVAH) had its price objective raised by investment analysts at BMO Capital Markets from $10.00 to $14.00 in a report released on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. BMO Capital Markets’ price objective would indicate a potential upside of 24.00% from the stock’s previous close.

AVAH has been the topic of a number of other reports. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Aveanna Healthcare in a research report on Thursday, July 2nd. Stephens upgraded shares of Aveanna Healthcare from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $10.00 to $11.00 in a research report on Friday, May 15th. Royal Bank Of Canada raised shares of Aveanna Healthcare from a “sector perform” rating to an “outperform” rating and set a $10.00 target price for the company in a research note on Wednesday, June 3rd. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Aveanna Healthcare in a research note on Friday. Finally, Truist Financial boosted their target price on Aveanna Healthcare from $9.00 to $11.00 and gave the company a “hold” rating in a research note on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $11.22.

Aveanna Healthcare Trading Up 24.8%

Shares of NASDAQ AVAH opened at $11.29 on Friday. The company has a current ratio of 1.47, a quick ratio of 1.47 and a debt-to-equity ratio of 5.35. Aveanna Healthcare has a one year low of $5.93 and a one year high of $11.54. The business has a 50-day moving average price of $8.86 and a two-hundred day moving average price of $7.73. The firm has a market capitalization of $2.46 billion, a PE ratio of 9.57, a PEG ratio of 0.90 and a beta of 1.90.

Aveanna Healthcare (NASDAQ:AVAH) last issued its earnings results on Thursday, August 13th. The company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.03. The company had revenue of $670.48 million for the quarter, compared to the consensus estimate of $638.61 million. Aveanna Healthcare had a return on equity of 124.68% and a net margin of 10.37%. As a group, analysts predict that Aveanna Healthcare will post 0.68 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Patrick A. Cunningham sold 125,000 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $7.59, for a total transaction of $948,750.00. Following the completion of the sale, the insider directly owned 212,755 shares of the company’s stock, valued at approximately $1,614,810.45. This represents a 37.01% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Robert M. Williams, Jr. sold 7,000,000 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $6.24, for a total transaction of $43,680,000.00. Following the sale, the insider owned 252,899 shares of the company’s stock, valued at $1,578,089.76. This trade represents a 96.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 31,305,664 shares of company stock worth $215,555,910. 5.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Aveanna Healthcare

Several hedge funds have recently modified their holdings of AVAH. Vanguard Group Inc. lifted its position in shares of Aveanna Healthcare by 38.0% in the 4th quarter. Vanguard Group Inc. now owns 5,577,010 shares of the company’s stock worth $45,564,000 after acquiring an additional 1,535,351 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Aveanna Healthcare by 49.5% during the first quarter. Dimensional Fund Advisors LP now owns 1,334,374 shares of the company’s stock valued at $8,593,000 after purchasing an additional 441,707 shares during the period. Segall Bryant & Hamill LLC increased its position in shares of Aveanna Healthcare by 425.8% during the first quarter. Segall Bryant & Hamill LLC now owns 163,966 shares of the company’s stock valued at $1,056,000 after purchasing an additional 132,779 shares during the period. Weiss Asset Management LP acquired a new position in shares of Aveanna Healthcare in the first quarter valued at $732,000. Finally, Smith Group Asset Management LLC raised its stake in shares of Aveanna Healthcare by 34.3% in the first quarter. Smith Group Asset Management LLC now owns 263,669 shares of the company’s stock valued at $1,698,000 after purchasing an additional 67,393 shares in the last quarter. 87.96% of the stock is owned by institutional investors.

Key Stories Impacting Aveanna Healthcare

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Quarterly results exceeded expectations. Aveanna reported adjusted earnings of $0.22 per share, above consensus estimates of approximately $0.17–$0.19, while revenue reached $670.5 million versus the $638.6 million consensus estimate. Revenue increased 13.7% year over year, and net income rose to $40.3 million from $27.0 million. Aveanna Healthcare second-quarter financial results
• Positive Sentiment: Management raised its 2026 financial targets. Full-year revenue guidance was increased to more than $2.68 billion from $2.63 billion–$2.65 billion, while adjusted EBITDA guidance rose to more than $365 million from $338 million–$342 million. Adjusted EBITDA for the quarter was $95.4 million, up 8% year over year. Aveanna Healthcare earnings call highlights
• Positive Sentiment: Analyst commentary was supportive. One analysis said the results reinforced its buy rating, citing Aveanna’s relatively low forward valuation and strong EBITDA margin compared with peers. The company’s Private Duty Services segment remains the main growth engine, accounting for roughly 83% of revenue. Aveanna Healthcare Q2 earnings analysis
• Neutral Sentiment: Investors are focusing on execution and the earnings-call outlook. The strong growth forecast supports the recent rally, but the stock’s valuation and elevated leverage may make it more sensitive to any slowdown in operating performance or guidance.
• Negative Sentiment: Gross-margin pressure remains a concern. Despite revenue growth, gross margins declined across Aveanna’s business segments. Continued margin compression could limit the benefit of higher revenue and make the upgraded EBITDA targets harder to sustain. Aveanna Healthcare Q2 2026 earnings call transcript

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.